Interstitial Lung Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with alpha-1 antitrypsin (AAT) deficiency who have a confirmed high-risk genetic type, along with symptoms, chest x-ray results, and breathing test results that show lung disease — this includes both current smokers (at least 1 pack per day for 2 or more years) and non-smokers or ex-smokers who have not smoked for 3 or more years.
• People with chronic obstructive pulmonary disease (a long-term lung condition) who have symptoms, chest x-ray results, and breathing test results consistent with lung disease — including both current smokers and people who have never smoked or stopped smoking 3 or more years ago.
• People with cystic fibrosis who have a known gene change linked to the condition, or whose symptoms and clinical features are consistent with cystic fibrosis; children with cystic fibrosis aged 8 and over may also be included.
• People already diagnosed with sarcoidosis, mycobacterial infections, tuberous sclerosis complex (TSC), cystic lung diseases, lymphangioleiomyomatosis, lymphatic disorders, a history of pneumothorax, pulmonary fibrosis, asthma, histiocytosis X, or diabetes mellitus.
• Relatives of patients with the conditions covered by this trial may also be seen under this study.
• Children aged 2 and over with lymphangiomatosis may be included.
• People with asthma may be enrolled at Suburban Hospital specifically.
• Healthy volunteers with no lung disease (for example, people with rheumatoid arthritis but no lung involvement) may join as a pulmonary control group.
• Healthy volunteers with no history of diabetes, coronary artery disease, or lung disease may join as a diabetes control group.
• Pregnant or nursing women may be included in the study, though certain procedures will not be carried out during pregnancy or while nursing, including breathing tests, the six-minute walk test, bronchoscopy, thoracentesis, and imaging tests involving contrast dye or radiation such as chest x-rays, CT scans, and MRIs.
• People with abnormalities in certain cell-level chemical processes known as ADP-ribosylation may be included; children aged 2 and over may be included if they have a known defect in this process, or if a family member has such a defect and the child may be affected.

Who may not be able to join:

• People younger than 18 or older than 90, with specific exceptions: NIH patients with the conditions described in this trial may be eligible from age 16; children with cystic fibrosis may be included from age 8; children aged 2 and over may be included if they have lymphangiomatosis or an ADP-ribosylation defect, or have a family member with such a defect; other age exceptions may apply if specific approval is granted by the relevant review board (confirm with trial site).
• People who are not able to complete reliable breathing (pulmonary function) tests; healthy volunteers, patient relatives (except those connected to ADP-ribosylation defects), and asthma patients from Suburban Hospital must be between 18 and 90 years of age.
• For the bronchoscopy (a camera procedure to look inside the airways) part of the study specifically, people who have any medical reason that makes this procedure unsafe are not eligible.
• People whose illness is at an advanced stage where the risk of the bronchoscopy procedure is considered significant, even if there is no specific named reason to avoid it.
• People with an allergy to local anaesthetic agents such as lidocaine are not eligible for the bronchoscopy portion.
• People who currently have, or have recently had, a respiratory infection within the last 4 weeks are not eligible for the bronchoscopy portion.
• People who are pregnant or breastfeeding are not eligible for the bronchoscopy portion.
• People younger than 18 or older than 65 are not eligible for the bronchoscopy portion.

Important: Always verify eligibility with the trial site directly before applying.